Search for: "OXLEY v. STATE"
Results 601 - 620
of 658
Sorted by Relevance
|
Sort by Date
23 May 2008, 1:03 am
Here is IP Think Tank’s weekly selection of top intellectual property news breaking in the blogosphere and internet. [read post]
5 Apr 2012, 12:34 pm
The emerging growth companies would still be required to comply with SEC-mandated quarterly and annual disclosures, but they would be exempted from the auditor attestation provisions of Section 404(b) of the Sarbanes-Oxley Act for a longer transition period, up to five years, instead of the current transition period of two years. [read post]
22 Mar 2015, 3:07 pm
Burwell Supreme Court Oral Argument Read Transcript of King v. [read post]
29 Jun 2009, 7:04 pm
FEC and Austin v. [read post]
14 Mar 2018, 12:46 am
That said, employees who report misconduct internally may still be entitled to anti-retaliation protection under the Sarbanes-Oxley Act. [read post]
21 Nov 2006, 11:25 am
Sarbanes-Oxley). [read post]
14 Jan 2009, 2:30 am
United States v. [read post]
3 Apr 2012, 9:45 am
V Expand the small public offering exemption The JOBS Act increase [read post]
10 Apr 2012, 3:01 pm
Study on the impact of State Blue Sky laws on Regulation A offerings.TITLE V--PRIVATE COMPANY FLEXIBILITY AND GROWTHSec. 501. [read post]
11 Apr 2024, 4:57 am
Emphasis on Individual Accountability to Protect the Markets To encourage a compliance culture, Associate Director Stacy Bogert stated that the SEC will seek clawbacks of executive compensation under Sarbanes-Oxley Section 304. [read post]
20 Jul 2011, 7:00 am
And in April 2011, in the case of AT&T Mobility v. [read post]
26 Feb 2007, 6:13 am
The Machine is Us/ing Us," created by Michael Wesch, Assistant Professor of Anthropology Kansas State University. [read post]
7 Mar 2008, 2:00 am
: (IPBiz), US: Proposals for the approval of generic biologics under consideration: (Pharmacapsules@Gowlings), US: A paradigm shift in obviousness for pharma, biotech: (IP Law360), US: USPTO’s Bruce Kisliuk addresses ACI Pharma/biotech patent claim drafting and prosecution conference: (Patent Docs), US: New bill to provide biotech companies Sarbanes-Oxley relief: (California Biotech Law Blog), US: Biotech and pharma companies spent millions on lobbying in 2007:… [read post]
4 Dec 2013, 6:27 am
In Millard v Miller, No. 05-C-103-S, 2005 U.S. [read post]
5 Nov 2014, 7:28 pm
Referring to last Term’s Bond v. [read post]
14 Nov 2014, 8:15 am
Affirming a $30,000 award to the employee, the appeals court also ruled that SOX affords noneconomic compensatory damages, including for emotional distress (Halliburton, Inc. v. [read post]
1 Feb 2010, 6:36 am
Editor’s Note: Eduardo Gallardo is a partner focusing on mergers and acquisitions at Gibson, Dunn & Crutcher LLP. [read post]
11 Aug 2009, 8:34 pm
Co. v. [read post]
11 Dec 2009, 11:38 am
The company's importance as a source of credit for households, businesses, and state and local governments must also be considered, as well as its source of liquidity for the financial system. [read post]
23 Apr 2010, 6:09 am
Stockholder Proposal Dynamics: the cumulative effects of seven years of post-Sarbanes-Oxley “precatory” stockholder proposals to dismantle all semblance of corporate takeover defenses, accompanied by the specter of “withheld” or “against” votes on director nominees if directors failed to dismantle defenses following favorable stockholder vote; and, 7. [read post]
